|Bid||0.000 x 1100|
|Ask||0.000 x 800|
|Day's Range||0.433 - 0.450|
|52 Week Range||0.380 - 0.920|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 10, 2016 - Mar 14, 2016|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.55|
LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on PBYI sign up now at www.wallstequities.com/registration. The Company's shares have gained 8.95% in the last month, 10.72% over the last three months, and 18.26% over the past year.
NEW YORK, June 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Virtu ...
Mucosal Improvement Observed in 61% of the Patients and 33% achieved Mucosal Healing. Clinical Responses Observed in 67% of the Patients and Clinical Remission Observed in 28% of the Patients. 89% of the ...
LONDON, UK / ACCESSWIRE / May 30, 2018 / If you want access to our free research report on Protalix BioTherapeutics, Inc. (NYSE: PLX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=PLX as the Company's latest news hit the wire. On May 25, 2018, the Biopharmaceutical Company, which is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system ProCellEx, declared that it showcased data from the Phase-III BALANCE Study in a poster presentation at the 55th ERA-EDTA Congress (European Renal Association - European Dialysis and Transplant Association). Active-Investors.com is currently working on the research report for G1 Therapeutics, Inc. (NASDAQ: GTHX), which also belongs to the Healthcare sector as the Company Protalix BioTherapeutics.
GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that a poster presentation on the characteristics of Fabry disease patients screened in the phase III BALANCE clinical trial of pegunigalsidase alfa, a PEGylated alfa galactosidase alfa enzyme, or PRX-102, for the treatment of Fabry disease was presented at the 55th ERA-EDTA Congress (European Renal Association – European Dialysis and Transplant Association).
Protalix BioTherapeutics, Inc. (the “Company”) (NYSE American:PLX) (PLX.TA) announced today that $3.42 million of the aggregate principal amount of the Company’s outstanding 4.5% Convertible Senior Notes due 2018 (the “Notes”) will be exchanged for 2,613,636 shares of the Company’s common stock and $2.27 million in cash. Additionally, the Company announced today that it has delivered the necessary funds under the indenture governing the Notes to effectively discharge the remaining outstanding Notes. Additional details regarding the exchange can be found in the Company’s Form 8-K to be filed with the Securities and Exchange Commission.
The Carmiel, Israel-based company said it had a loss of 6 cents per share. The drug developer posted revenue of $4.6 million in the period. The company's shares closed at 40 cents. A year ago, they were ...
CARMIEL, Israel, May 09, 2018-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary ...
CARMIEL, Israel, April 26, 2018-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its ...
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Athersys, Inc. (NASDAQ: ATHX ) stock gained more than ...
Protalix BioTherapeutics Inc’s (AMEX:PLX): Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in IsraelRead More...
NEW YORK, NY / ACCESSWIRE / March 6, 2018 / Protalix Biotherapeutics, Inc. (NYSE American: PLX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 6, 2018, at 8:30 ...
Protalix Biotherapeutics Inc (NYSE:PLX) stock is riding a nearly 10% gain this morning after the Israeli biotech firm unleashed positive interim data from its Phase II clinical study in ulcerative colitis (UC). The trial is investigating the company's oral anti-TNF drug OPRX-106, with data set loose from the first 14 patients who have completed the randomized, open label, two-arm study. A total of 24 patients were enrolled and randomized to receive 2 mg or 8 mg of OPRX-106, administered orally, once daily, for 8 weeks. The first 14 patients have completed the study, and four patients are currently in treatment and follow-up. The trial evaluated key efficacy endpoints including clinical response and remission utilizing the Mayo score, as well as safety and pharmacokinetics.